Controlled Equity OfferingSM Sales AgreementSpero Therapeutics, Inc. • March 11th, 2021 • Pharmaceutical preparations • New York
Spero Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 11th, 2021 • Spero Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Executive Employment Agreement (this “Agreement”) is made and entered into this 9th day of December, 2020 (the “Effective Date”) by and between Spero Therapeutics, Inc., a Delaware corporation (“Company”), and Satyavrat Shukla (“Executive”).
AMENDED AND RESTATED LICENSE AGREEMENTAmended and Restated License Agreement • March 11th, 2021 • Spero Therapeutics, Inc. • Pharmaceutical preparations
This AMENDED AND RESTATED LICENSE AGREEMENT (this “Agreement”) , effective as of January 15, 2021 (the “Amendment Effective Date”), is entered into by and among Everest Medicines II Limited, a company incorporated under the laws of the Cayman Islands (“Everest”) having its registered office at Vistra (Cayman) Limited, P. O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 – 1205, Cayman Islands; Spero Therapeutics, Inc., a Delaware corporation (“Spero”) having its principal place of business at 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts, 02139; and, solely for purposes of Section 3.3(e) (with respect to the SPR741 Option), Spero Potentiator, Inc., a Delaware corporation (“Potentiator”) having its principal place of business at 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts, 02139. Everest, Spero and Potentiator are referred to individually as a “Party” and collectively as the “Parties.”
